The US Food and Drug Administration (FDA) has granted approval for Irish medical technology firm Medtronic‘s Protégé GPS self-expanding peripheral stent system to treat stenotic lesions of the common and external iliac arteries.

Iliac stenosis occurs when plaque builds up in the iliac artery, which can block blood supply to the entire leg causing pain and eventually leading to reduced mobility.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Approval was based on the nine-month results from a prospective, multi-centre, non-randomised Durability Iliac study, which showed the safety and effectiveness of the stent system in the treatment of stenotic lesions of the common and external iliac arteries.

The trial showed 95.8% nine-month primary patency by Kaplan-Meier analysis and 98.6% freedom from target vessel revascularisation.

Mount Sinai School of Medicine co-national principal investigator of the Durability Iliac study Dr Peter Faries said: "When used for iliac angioplasty and stenting, the Protégé GPS self-expanding peripheral stent system demonstrated excellent patency rates even in difficult-to-treat calcified lesions.

"The trial showed 95.8% nine-month primary patency by Kaplan-Meier analysis and 98.6% freedom from target vessel revascularisation."

"Data from the Durability Iliac study confirms the safety and effectiveness of the Protégé GPS stent."

The system helps physicians to treat iliac artery lesions and restore blood flow with large diameter stents through a low and 6F profile delivery system.

The stent is cut from a nitinol tube into an open lattice design and has tantalum radiopaque markers at the proximal and distal ends.

Following deployment, the stent achieves its predetermined diameter and exerts a constant, outward force to restore patency.

Medtronic aortic and peripheral vascular business medical director Dr Mark Turco said: "The Protégé GPS self-expanding peripheral stent system is designed to enhance delivery, deployment and visibility during peripheral vascular procedures.

"This new indication will provide physicians with enhanced device options when treating complex iliac artery disease."